NO982417L - Vektorer og fremgangsmÕter for genoverf°ring til celler - Google Patents

Vektorer og fremgangsmÕter for genoverf°ring til celler

Info

Publication number
NO982417L
NO982417L NO982417A NO982417A NO982417L NO 982417 L NO982417 L NO 982417L NO 982417 A NO982417 A NO 982417A NO 982417 A NO982417 A NO 982417A NO 982417 L NO982417 L NO 982417L
Authority
NO
Norway
Prior art keywords
coat protein
cells
vector
methods
chimeric
Prior art date
Application number
NO982417A
Other languages
English (en)
Other versions
NO982417D0 (no
Inventor
Thomas J Wickham
Imre Kovesdi
Douglas E Brough
Original Assignee
Genvec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/563,368 external-priority patent/US5965541A/en
Priority claimed from US08/700,846 external-priority patent/US5962311A/en
Priority claimed from US08/701,124 external-priority patent/US5846782A/en
Application filed by Genvec Inc filed Critical Genvec Inc
Publication of NO982417D0 publication Critical patent/NO982417D0/no
Publication of NO982417L publication Critical patent/NO982417L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

Det er beskrevet et chimerisk adenovirus kappeprotein som er forskjellig fra vild-type kapperprotein ved introduksjon av en nonnativ aminosyresekvens. Ht slikt chimerisk adenovirus kappeprotein har evnen til å lede innførsel i cellene til en vektor omfattende kappeproteinet som er mer effektivt enn innførsel i cellene til en vektor som er identisk med unntagelse av at den omfatter et vild-type adenovirus kappeprotein isteden for chimerisk adenovirus kappeprotein. Det crumeriske kappeproteinet er fortrinnsvis et fiber, hekson eller pentonprotein. Det er videre beskrevet en adenoviral vektor som omfatter chimerisk adenovirus kappeprotein samt fremgangsmåte for konstruering og andvendelse av en slik vektor.
NO982417A 1995-11-28 1998-05-27 Vektorer og fremgangsmÕter for genoverf°ring til celler NO982417L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/563,368 US5965541A (en) 1995-11-28 1995-11-28 Vectors and methods for gene transfer to cells
US08/700,846 US5962311A (en) 1994-09-08 1996-08-21 Short-shafted adenoviral fiber and its use
US08/701,124 US5846782A (en) 1995-11-28 1996-08-21 Targeting adenovirus with use of constrained peptide motifs
PCT/US1996/019150 WO1997020051A2 (en) 1995-11-28 1996-11-27 Vectors and methods for gene transfer to cells

Publications (2)

Publication Number Publication Date
NO982417D0 NO982417D0 (no) 1998-05-27
NO982417L true NO982417L (no) 1998-07-06

Family

ID=27415918

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982417A NO982417L (no) 1995-11-28 1998-05-27 Vektorer og fremgangsmÕter for genoverf°ring til celler

Country Status (17)

Country Link
EP (3) EP0863987B1 (no)
JP (1) JP3420586B2 (no)
AT (1) ATE382694T1 (no)
AU (1) AU724189B2 (no)
BG (1) BG102554A (no)
BR (1) BR9612685A (no)
CA (1) CA2236912C (no)
CZ (1) CZ162398A3 (no)
EA (1) EA199800475A1 (no)
EE (1) EE9800160A (no)
IL (1) IL124654A0 (no)
IS (1) IS4754A (no)
NO (1) NO982417L (no)
NZ (1) NZ323834A (no)
PL (1) PL327038A1 (no)
SK (1) SK72298A3 (no)
WO (1) WO1997020051A2 (no)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6465253B1 (en) 1994-09-08 2002-10-15 Genvec, Inc. Vectors and methods for gene transfer to cells
US5962311A (en) * 1994-09-08 1999-10-05 Genvec, Inc. Short-shafted adenoviral fiber and its use
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same
FR2761689B1 (fr) * 1997-04-02 1999-06-25 Transgene Sa Fibre adenovirale modifiee et adenovirus cibles
CA2307842C (en) 1997-10-31 2010-10-19 The Board Of Regents Of The University Of Oklahoma Hyaluronan synthase gene and uses thereof
JP2002508967A (ja) * 1998-01-16 2002-03-26 ジェンザイム・コーポレイション 修飾カプシド蛋白を有するアデノウイルスベクター
US20030017138A1 (en) * 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
JP2002523105A (ja) 1998-08-27 2002-07-30 アバンテイス・フアルマ・エス・アー 異種遺伝子の運搬用の標的化アデノウイルスベクター
EP1020529B1 (en) * 1998-11-20 2005-06-01 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
IL133032A (en) * 1998-11-20 2007-06-03 Introgene Bv Adenoviral gene delivery vectors provided with a tissue tropism for smooth muscle cells and /or endothelial cells
JP4683727B2 (ja) * 1999-03-04 2011-05-18 クルーセル ホランド ベスローテン フェンノートシャップ 線維芽細胞様またはマクロファージ様細胞の形質導入のための手段と方法
AU763733B2 (en) * 1999-07-06 2003-07-31 Got-A-Gene Ab Recombinant adenovirus
US6955808B2 (en) * 1999-09-24 2005-10-18 Uab Research Foundation Capsid-modified recombinant adenovirus and methods of use
EP1276888A2 (en) * 2000-04-26 2003-01-22 Crucell Holland B.V. Adenovirus vectors with knobless fibers, and their uses
AU6368901A (en) * 2000-05-31 2001-12-11 Univ Saskatchewan Modified bovine adenovirus having altered tropism
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
GB0017720D0 (en) * 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
US6573092B1 (en) 2000-10-10 2003-06-03 Genvec, Inc. Method of preparing a eukaryotic viral vector
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
US7611868B2 (en) 2003-05-14 2009-11-03 Instituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Recombinant modified adenovirus fiber protein
EP1687032B1 (en) 2003-11-14 2010-02-24 Genvec, Inc. Pharmaceutical composition for treating unresectable, locally advanced pancreatic cancer (lapc).
JP2007228802A (ja) * 2004-03-31 2007-09-13 Dnavec Research Inc 標的細胞への遺伝子の導入方法
JP2007532656A (ja) 2004-04-12 2007-11-15 アメリカ合衆国 アデノウイルスベクターを用いて免疫応答を誘導するための方法
WO2006033679A2 (en) 2004-05-25 2006-03-30 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
WO2007027860A2 (en) 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
BRPI0618441B8 (pt) 2005-11-10 2021-07-27 Genvec Inc vetor adenoviral
EP2018156B1 (en) 2006-04-07 2010-03-17 Chimeros, Inc. Compositions and methods for treating b- cell malignancies
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
WO2011057248A2 (en) 2009-11-09 2011-05-12 Genvec, Inc. Simian adenovirus and methods of use
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
US8920813B2 (en) 2010-12-20 2014-12-30 Genvec, Inc. Adenoviral vector-based dengue fever vaccine
CA2847888A1 (en) 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
WO2013154744A1 (en) * 2012-04-13 2013-10-17 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
EP2855669B1 (en) 2012-05-29 2018-10-10 GenVec, Inc. Modified serotype 28 adenoviral vectors
AU2013296218B2 (en) 2012-08-03 2019-07-18 Cedars-Sinai Medical Center Isolating traffic-enhancing mutants of drug delivery protein
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
KR102471633B1 (ko) 2016-02-23 2022-11-25 솔크 인스티튜트 포 바이올로지칼 스터디즈 바이러스 동역학에 미치는 영향 최소화를 위한 치료용 아데노바이러스의 외인성 유전자 발현
EP3390428B1 (en) 2016-02-23 2019-09-25 Salk Institute for Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2018064523A1 (en) 2016-09-30 2018-04-05 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into t cells
JP2019536468A (ja) 2016-12-12 2019-12-19 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍を標的にする合成アデノウイルスおよびその使用
JP2023506768A (ja) 2019-12-12 2023-02-20 ティン セラピューティックス エルエルシー 聴覚損失の予防及び治療のための組成物及び方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same

Also Published As

Publication number Publication date
AU724189B2 (en) 2000-09-14
NZ323834A (en) 2000-01-28
MX9804203A (es) 1998-10-31
WO1997020051A2 (en) 1997-06-05
SK72298A3 (en) 1998-12-02
EP1518933A1 (en) 2005-03-30
PL327038A1 (en) 1998-11-09
EA199800475A1 (ru) 1998-12-24
CA2236912C (en) 2006-04-25
WO1997020051A3 (en) 1997-08-28
EP0863987A2 (en) 1998-09-16
IS4754A (is) 1998-05-25
AU1086897A (en) 1997-06-19
BR9612685A (pt) 1999-07-20
EP0863987B1 (en) 2008-01-02
JPH11501219A (ja) 1999-02-02
EE9800160A (et) 1998-12-15
NO982417D0 (no) 1998-05-27
IL124654A0 (en) 1998-12-06
CZ162398A3 (cs) 1998-10-14
JP3420586B2 (ja) 2003-06-23
ATE382694T1 (de) 2008-01-15
CA2236912A1 (en) 1997-06-05
BG102554A (en) 1999-04-30
EP1616961A1 (en) 2006-01-18

Similar Documents

Publication Publication Date Title
NO982417D0 (no) Vektorer og fremgangsmÕter for genoverf°ring til celler
ATE382695T1 (de) Targeting von adenoviren mit hilfe von konformationsbeschränkten peptidmotiven
ATE213022T1 (de) Adenovirale vektoren für die gentherapie
DE69637545D1 (de) Chimärisches , adenovirales faserprotein und verfahren zu dessen verwendung
EP0866721A4 (en) ADENOVIRAL TARGET VECTORS
SG165153A1 (en) Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
ATE336587T1 (de) Adenoviren-vektor systeme und zelllinien
DE69535103D1 (de) Rekombinanter adenovirus welcher eine chimäre penton-base aufweist
ATE342350T1 (de) Modifizierte adenoviren welche ein faserersatzprotein enthalten
DK0632129T3 (da) Rekombinante foamy-virusvektorer til medicinsk og diagnostisk anvendelse, og fremgangsmåder til at præparere rekombinante foamy-virusvektorer
CA2252493A1 (en) .beta.-galactoside - .alpha. 2,6-sialyltransferase gene
WO2000009693A3 (en) Identification of the gene causing the mouse scurfy phenotype and its human ortholog
WO2002086098A3 (en) A lac operator-repressor system
DK0843731T3 (da) Adenovirusvektorer til genterapi
MX9706290A (es) Secuencias amplificadoras, vectores que portan estas secuencias y sus utilizaciones en composiciones para la expresion de secuencias nucleotidicas en celulas transfectadas, aplicaciones terapeuticas y vacunales.
NO951315D0 (no) Ökt produksjon av utsondrede proteiner fra rekombinante eukaryote-celler
EP0723014A3 (en) cDNA of DOCK180 gene and DOCK180 protein
CA2237059A1 (en) Targeted adenovirus vectors
TH19876A (th) จีนที่ประมวลรหัสและวิธีสำหรับแสดงลักษณะเอนไซม์ชนิดใหม่
IT1276724B1 (it) Vettore plasmidico di espressione per cellule di mammifero

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application